Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies
Purpose: To report two new cases and summarize one case of uveal melanoma following treatment of hematologic malignancies with Bruton's tyrosine kinase inhibitors. Observations: A 71-year-old male, with a history of Waldenstrom macroglobulinemia treated with an anti-CD20 antibody and BTKi, was...
| الحاوية / القاعدة: | American Journal of Ophthalmology Case Reports |
|---|---|
| المؤلفون الرئيسيون: | , , |
| التنسيق: | مقال |
| اللغة: | الإنجليزية |
| منشور في: |
Elsevier
2025-06-01
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | http://www.sciencedirect.com/science/article/pii/S2451993625000982 |
| _version_ | 1849404701119873024 |
|---|---|
| author | Tara Murty Jonathan H. Lin Prithvi Mruthyunjaya |
| author_facet | Tara Murty Jonathan H. Lin Prithvi Mruthyunjaya |
| author_sort | Tara Murty |
| collection | DOAJ |
| container_title | American Journal of Ophthalmology Case Reports |
| description | Purpose: To report two new cases and summarize one case of uveal melanoma following treatment of hematologic malignancies with Bruton's tyrosine kinase inhibitors. Observations: A 71-year-old male, with a history of Waldenstrom macroglobulinemia treated with an anti-CD20 antibody and BTKi, was diagnosed with a choroidal melanoma with intraocular metastasis. A 73-year-old female, with a history of Mantle Cell Lymphoma treated with an alkylating chemotherapy and an anti-CD20 antibody, relapse, and subsequent treatment with BTKi, was diagnosed with a uveal melanoma. Conclusions and Importance: Patients being treated with BTK inhibitors may be at higher risk for the development of uveal melanoma. Based on our findings, we recommend increased surveillance of this patient population for secondary primary or metastatic uveal melanoma. Continued documentation of occurrence in conjunction with research at a molecular and cellular level are warranted to better understand the impact of systemic cancer therapies on secondary malignancies. |
| format | Article |
| id | doaj-art-4ee0f71c8b08441c9dee5c6475ee55ca |
| institution | Directory of Open Access Journals |
| issn | 2451-9936 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| spelling | doaj-art-4ee0f71c8b08441c9dee5c6475ee55ca2025-08-20T03:54:01ZengElsevierAmerican Journal of Ophthalmology Case Reports2451-99362025-06-013810234510.1016/j.ajoc.2025.102345Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignanciesTara Murty0Jonathan H. Lin1Prithvi Mruthyunjaya2Byers Eye Institute, Stanford University, Palo Alto, CA, USADepartment of Pathology, Stanford University, Palo Alto, CA, USAByers Eye Institute, Stanford University, Palo Alto, CA, USA; Corresponding author. Stanford Byers Eye Institute, 2452 Watson Ct, MC 5353, Palo Alto, CA, 94303, USA.Purpose: To report two new cases and summarize one case of uveal melanoma following treatment of hematologic malignancies with Bruton's tyrosine kinase inhibitors. Observations: A 71-year-old male, with a history of Waldenstrom macroglobulinemia treated with an anti-CD20 antibody and BTKi, was diagnosed with a choroidal melanoma with intraocular metastasis. A 73-year-old female, with a history of Mantle Cell Lymphoma treated with an alkylating chemotherapy and an anti-CD20 antibody, relapse, and subsequent treatment with BTKi, was diagnosed with a uveal melanoma. Conclusions and Importance: Patients being treated with BTK inhibitors may be at higher risk for the development of uveal melanoma. Based on our findings, we recommend increased surveillance of this patient population for secondary primary or metastatic uveal melanoma. Continued documentation of occurrence in conjunction with research at a molecular and cellular level are warranted to better understand the impact of systemic cancer therapies on secondary malignancies.http://www.sciencedirect.com/science/article/pii/S2451993625000982Uveal melanomaBruton's tyrosine kinase inhibitorHematologic malignancy |
| spellingShingle | Tara Murty Jonathan H. Lin Prithvi Mruthyunjaya Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies Uveal melanoma Bruton's tyrosine kinase inhibitor Hematologic malignancy |
| title | Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies |
| title_full | Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies |
| title_fullStr | Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies |
| title_full_unstemmed | Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies |
| title_short | Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies |
| title_sort | uveal melanoma following bruton s tyrosine inhibitor use for the treatment of hematologic malignancies |
| topic | Uveal melanoma Bruton's tyrosine kinase inhibitor Hematologic malignancy |
| url | http://www.sciencedirect.com/science/article/pii/S2451993625000982 |
| work_keys_str_mv | AT taramurty uvealmelanomafollowingbrutonstyrosineinhibitoruseforthetreatmentofhematologicmalignancies AT jonathanhlin uvealmelanomafollowingbrutonstyrosineinhibitoruseforthetreatmentofhematologicmalignancies AT prithvimruthyunjaya uvealmelanomafollowingbrutonstyrosineinhibitoruseforthetreatmentofhematologicmalignancies |